You are here

Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

Last updated on March 11, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, 85006 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50-89 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of probable Alzheimer Disease according to National Institute of
Neurological and Communicative Disorders and Stroke/Alzheimer`s Disease and Related
Disorders Association (NINCDS/ADRDA) criteria

- Mini-Mental State Examination (MMSE) score 16-26

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Magnetic Resonance Imaging (MRI) showing other brain abnormalities

- Other diagnosed neurological or psychiatric disorders

NCT00663026
Pfizer
Completed
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now